Psychiatry and Neurology, Neurology · Caguas, PR
NPI
1467868927
Since 2014
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
4
Medicare group memberships
Hospitals
0
Hospital affiliations
Hima Plaza 1 Ave Degetau Suite 308-311
Caguas, PR, 00725
Phone (787) 930-1705
Groups this clinician bills Medicare through
Medicare paid, 2023
$706
16 services
Medicare patients, 2023
12
Average age 71
Drug cost, 2024
$3.1M
811 prescriptions
Company payments, 2025
$91K
From 16 companies
Medicare prescription drug claims, 2024
In 2024, the drug Jose Avila Ornelas prescribed most often to Medicare patients was Kesimpta Pen (Ofatumumab), with 90 prescriptions and refills. In total Jose Avila Ornelas wrote 811 Medicare prescriptions that cost $3.1M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-08-18.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Kesimpta Pen Ofatumumab | 90 | 90 | 11 | $808K |
| Baclofen Generic | 70 | 74 | 19 | $1,068 |
| Vumerity Diroximel Fumarate | 59 | 59 | Under 11 | $522K |
| Gabapentin Generic | 57 | 57 | Under 11 | $592 |
| Emgality Pen Galcanezumab-Gnlm | 41 | 41 | Under 11 | $31K |
| Dalfampridine Er Dalfampridine | 40 | 40 | Under 11 | $2,776 |
| Mayzent Siponimod | 36 | 36 | Under 11 | $349K |
| Pregabalin Generic | 29 | 29 | Under 11 | $902 |
| Carbamazepine Generic | 27 | 27 | Under 11 | $379 |
| Enspryng Satralizumab-Mwge | 24 | 24 | Under 11 | $414K |
| Emgality Syringe Galcanezumab-Gnlm | 23 | 23 | Under 11 | $16K |
| Tizanidine Hcl Generic | 21 | 21 | Under 11 | $164 |
| Bafiertam Monomethyl Fumarate | 20 | 20 | Under 11 | $134K |
| Levetiracetam Generic | 17 | 21 | Under 11 | $302 |
| Primidone Generic | 17 | 17 | Under 11 | $216 |
Brand drugs: 338 claims; generic drugs: 473 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jose Avila Ornelas $91K ($89K in general payments such as food, travel and fees and $1,996 for research) from 16 companies. The largest payer was Biogen, Inc. with $33K.
| Company | Payments | Amount |
|---|---|---|
| Biogen, Inc. BIIB | 44 | $33K |
| EMD Serono, Inc. MRK.DE | 25 | $24K |
| Alexion Pharmaceuticals, Inc. AZN | 26 | $19K |
| Amgen Inc. AMGN | 15 | $12K |
| Novartis Pharmaceuticals Corporation NVS | 28 | $1,204 |
| E.R. Squibb & Sons, L.L.C. BMY | 16 | $527 |
| TG Therapeutics, Inc. TGTX | 4 | $333 |
| Abbvie Inc. ABBV | 10 | $260 |
| Genentech USA, Inc. ROG.SW | 8 | $178 |
| Genentech, Inc. ROG.SW | 1 | $139 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.